Development of biomimetic mouldable osseous scaffold engineered from bioactive decellularized extracellular matrix-polymer-gel composite: a potential bone substitute.
R P., Pathak R., Kumar D., Obli Rajendran V., Kamalesh KS., Saikumar T.
Animal Study, published in Cell Tissue Bank (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cell Tissue Bank (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42573640
- DOI
- 10.1007/s10561-026-10244-0
Abstract (original English)
Abstract Critical-sized bone defects remain a major clinical challenge in veterinary orthopaedics due to limited intrinsic regenerative capacity and the drawbacks of conventional grafting options. This study reports the development and systematic evaluation of a novel bioinspired osseous scaffold engineered from decellularized bubaline cancellous bone granules, collagen gel, and polycaprolactone, with optional enrichment using autologous adipose-derived stromal vascular fraction. Scaffold physicochemical characteristics—including porosity, material density, and ultrastructure—were assessed through liquid displacement assays, histomorphometry, and scanning electron microscopy, confirming complete decellularization, interconnected porosity, and favourable matrix architecture. Mechanical testing demonstrated significantly enhanced tensile strength in the composite scaffold compared with plain acellular bone–collagen constructs. In vitro biocompatibility was validated by adipose derived mesenchymal stem cell adhesion, proliferation, and migration, with DAPI staining confirming uniform cellular distribution and robust scaffold–cell interactions, along with Alizarin Red S Staining for assessment of osteogenic mineralization.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.